Eleven Therapeutics Ltd. has established a research collaboration with Novo Nordisk A/S for the identification of novel molecules that promote precise delivery of nucleic acid for cardiometabolic diseases by leveraging Eleven’s innovative Deliveri platform.
Writing in The Journal of Enzyme Inhibition and Medicinal Chemistry, researchers from Nantong First People’s Hospital and collaborators recently conducted a study to discover Hsp90 inhibitors with high efficacy and broad antitumor activity.
Cumulus Oncology Ltd. and Leadxpro AG have signed a research collaboration focused on the discovery and development of small molecules targeting an undisclosed and novel cancer-focused G protein-coupled receptor (GPCR).
Researchers from Peking University (PKU) recently presented the discovery and preclinical evaluation of a novel small-molecule inhibitor of pan-αv integrin, C19-9-21, being developed for the treatment of prostate cancer.
Research led by Columbia University investigators has shed light on the immune pathway of the intestinal damage caused in celiac disease after gluten consumption. As reported in the July 14, 2023, issue of Science Immunology, the investigators showed an important role for cytotoxic T cells in addition to gluten-specific CD4+ T cells in the onset of celiac disease symptoms in a range of people with the condition.
Aligos Therapeutics Inc. has disclosed programmed cell death protein 1 (PD-1; PDCD1; CD279), PD-1 ligand 1 (PD-L1; CD274) and/or PD-1/PD-L1 interaction inhibitors reported to be useful for the treatment of hepatocellular carcinoma and hepatitis B virus (HBV).
Researchers from Astrazeneca plc have presented a novel adeno-associated virus (AAV)-delivered human (h)IL-33 neutralizing scFv-based protein construct at the 2023 World Congress on Basic and Clinical Pharmacology.
Researchers from Anhui Medical University (AMU) and Wuhan University of Technology (WUT) presented the discovery of novel acetylcholinesterase (AChE) inhibitors as potential disease-modifying anti-Alzheimer’s disease (AD) candidates.
Researchers from the U.S. National Cancer Institute and collaborators had previously demonstrated the therapeutic efficacy of an autologous whole tumor cell vaccine, named rWTC-MBTA, to prevent primary tumor growth and enhance mouse survival in a colon carcinoma model. The vaccine is composed of irradiated entire tumor cells (rWTC) pulsed with mannan-BAM (a pathogen-associated molecular pattern), TLR agonists and anti-CD40 antibody (MBTA).
Half of patients with HER2-positive advanced breast cancer develop metastases in the central nervous system (CNS), even while receiving HER2-directed therapies.
RSS
